• Press Release

Mount Sinai Health System Launches Collaboration With the Regeneron Genetics Center

  • New York, NY
  • (November 09, 2016)

Mount Sinai Health System today announced it will extend its work with Regeneron Pharmaceuticals, Inc. through a collaboration with its wholly owned subsidiary, the Regeneron Genetics Center (RGC), to perform whole exome sequencing on 33,000 DNA and plasma samples housed in Mount Sinai’s BioMe™ Biobank, one of the first biobank repositories in the country to link DNA sequencing data to clinical information stored within the electronic medical record (EMR).  

“The Mount Sinai BioMe Biobank is distinguished by its rich diversity in patient populations linked to electronic medical records,” said Judy Cho, MD, Ward-Coleman Professor of Translational Genetics and Medicine and Director of The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai. “We are extremely pleased to enter into this collaboration with the RGC to develop high-quality sequence data from the BioMe cohort. This partnership provides an important means of more effectively personalizing medical care throughout the Mount Sinai Health System.”

The BioMe Biobank constitutes one of the largest collection of samples collections in the United States that can be used for the analysis and sequencing of genetic material and comparison to long-term health outcomes. The RGC will perform whole exome sequencing to generate de-identified genomic data and analyze that data alongside EMRs, in order to discover actionable insights about human diseases that may be applied to drug discovery and development. The size and scope of the study, one of the largest of its kind, are meant to allow greater precision in identifying and validating the associations between genes and human disease, and potentially pinpointing more effective therapies for patients.

“We are excited to work with Regeneron, global leaders in advanced sequencing technology, analysis and translational medicine,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners. “This has the potential to dramatically change outcomes, ensuring a deeper understanding of disease and paving the way for therapeutic discoveries.”

“This marks Regeneron’s second recent collaboration with Mount Sinai, an important neighbor in the New York bioscience community,” said Alan Shuldiner, MD, Vice President and Co-Head of the Regeneron Genetics Center. “The pairing of Mount Sinai’s clinical excellence and Regeneron’s expertise in genetics-based research and therapeutic development holds enormous promise for discoveries that could ultimately benefit patients around the globe.”


About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.